2021
Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms
Deng S, Fan Z, Xia H, Gong Y, Qian Y, Huang Q, Cheng H, Jin K, Xiao Z, Luo G, Yu X, Liu C. Fibrinogen/Albumin Ratio as a Promising Marker for Predicting Survival in Pancreatic Neuroendocrine Neoplasms. Cancer Management And Research 2021, 13: 107-115. PMID: 33447083, PMCID: PMC7802789, DOI: 10.2147/cmar.s275173.Peer-Reviewed Original ResearchProgression-free survivalFibrinogen/albumin ratioIndependent risk factorOverall survivalPoor OSPan-NENsCutoff valuePrognostic valueMultivariate analysisAssociated with poor OSRisk factorsGrade 3 tumorsStage IV tumorsOptimal cutoff valuePancreatic neuroendocrine neoplasmsNonfunctioning tumorsIV tumorsNeuroendocrine neoplasmsPrimary endpointSecondary endpointsPredictive biomarkersClinicopathological characteristicsPredicting prognosisUnivariate analysisPredicting survival
2014
Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin, plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma.
George T, Ivey A, Daily K, Dang L, Watson S, Granicz R, Tormes K, Lu X, Liu C, Allegra C, Behrns K, Hughes S, Ogunwobi O, Trevino J. Src inhibition through a phase II study of 5-fluorouracil, oxaliplatin, plus dasatinib (FOLFOX-D) in first-line metastatic pancreatic adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 319-319. DOI: 10.1200/jco.2014.32.3_suppl.319.Peer-Reviewed Original ResearchMetastatic pancreatic cancerProgression-free survivalGrade 3 AEsOverall survivalOral multi-tyrosine kinase inhibitorMedian progression-free survivalMulti-tyrosine kinase inhibitorSrc inhibitionAdequate organ functionBiochemical response rateECOG PS 0Grade 4 AEsGrade 5 toxicityRECIST measurable diseaseTriplet combination therapyPhase II studyMetastatic pancreatic adenocarcinomaClinical unmet needPredictors of responseQuality of lifeEligible ptsMFOLFOX6 chemotherapyMeasurable diseasePrior therapySecondary endpoints